Triggiani M, Cirillo R, Lichtenstein L M, Marone G
Department of Medicine, University of Naples II School of Medicine, Italy.
Int Arch Allergy Appl Immunol. 1989;88(1-2):253-5. doi: 10.1159/000234801.
Cyclosporin A (CsA) is now widely used in the prevention/treatment of graft rejection and in the treatment of some human inflammatory diseases. We studied the effect of CsA on the release of chemical mediators from human lung mast cells in vitro. CsA (0.03-3 micrograms/ml) inhibited the release of histamine and prostaglandin D2 induced by anti-IgE from lung mast cells. CsA-induced inhibition of mediator release was not abolished by washing the cells before stimulation and it was not affected by the degree of purity of mast cell preparations. Our results indicate that CsA, in pharmacological concentrations, is a rapid and irreversible inhibitor of the release of preformed and de novo synthesized mediators from human lung mast cells. These findings might explain, at least in part, some of the therapeutic actions of CsA in vivo.
环孢素A(CsA)目前广泛应用于预防/治疗移植排斥反应以及治疗某些人类炎症性疾病。我们在体外研究了CsA对人肺肥大细胞释放化学介质的影响。CsA(0.03 - 3微克/毫升)抑制了抗IgE诱导的肺肥大细胞组胺和前列腺素D2的释放。刺激前洗涤细胞并不能消除CsA诱导的介质释放抑制作用,且其不受肥大细胞制剂纯度的影响。我们的结果表明,药理浓度的CsA是从人肺肥大细胞释放预先形成和重新合成介质的快速且不可逆的抑制剂。这些发现可能至少部分解释了CsA在体内的一些治疗作用。